Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease.

3-chymotrypsin-like protease 3CLpro COVID-19 SARS-CoV-2 catalytic dyad catalytic rate thermodynamic stability

Journal

Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988

Informations de publication

Date de publication:
2021
Historique:
received: 07 04 2021
accepted: 14 06 2021
entrez: 12 7 2021
pubmed: 13 7 2021
medline: 13 7 2021
Statut: epublish

Résumé

Coronaviruses are responsible for multiple pandemics and millions of deaths globally, including the current pandemic of coronavirus disease 2019 (COVID-19). Development of antivirals against coronaviruses, including the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) responsible for COVID-19, is essential for containing the current and future coronavirus outbreaks. SARS-CoV-2 proteases represent important targets for the development of antivirals because of their role in the processing of viral polyproteins. 3-Chymotrypsin-like protease (3CLpro) is one such protease. The cleavage of SARS-CoV-2 polyproteins by 3CLpro is facilitated by a Cys145-His41 catalytic dyad. We here characterized the catalytic roles of the cysteine-histidine pair for improved understanding of the 3CLpro reaction mechanism, to inform the development of more effective antivirals against Sars-CoV-2. The catalytic dyad residues were substituted by site-directed mutagenesis. All substitutions tested (H41A, H41D, H41E, C145A, and C145S) resulted in a complete inactivation of 3CLpro, even when amino acids with a similar catalytic function to that of the original residues were used. The integrity of the structural fold of enzyme variants was investigated by circular dichroism spectroscopy to test if the catalytic inactivation of 3CLpro was caused by gross changes in the enzyme secondary structure. C145A, but not the other substitutions, shifted the oligomeric state of the enzyme from dimeric to a higher oligomeric state. Finally, the thermodynamic stability of 3CLpro H41A, H41D, and C145S variants was reduced relative the wild-type enzyme, with a similar stability of the H41E and C145A variants. Collectively, the above observations confirm the roles of His41 and Cys145 in the catalytic activity and the overall conformational fold of 3CLpro SARS-CoV-2. We conclude that the cysteine-histidine pair should be targeted for inhibition of 3CLpro and development of antiviral against COVID-19 and coronaviruses.

Identifiants

pubmed: 34249864
doi: 10.3389/fchem.2021.692168
pii: 692168
pmc: PMC8264439
doi:

Types de publication

Journal Article

Langues

eng

Pagination

692168

Informations de copyright

Copyright © 2021 Ferreira, Fadl, Villanueva and Rabeh.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Chemotherapy. 2019;64(5-6):215-223
pubmed: 32259829
Chem Rev. 2002 Dec;102(12):4501-24
pubmed: 12475199
Virology. 2016 Jul;494:225-35
pubmed: 27128350
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22
pubmed: 16581910
J Chin Med Assoc. 2020 Mar;83(3):217-220
pubmed: 32134861
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):12997-13002
pubmed: 27799534
mSystems. 2020 Jul 28;5(4):
pubmed: 32723797
Science. 2003 Jun 13;300(5626):1763-7
pubmed: 12746549
Cell Host Microbe. 2020 Mar 11;27(3):325-328
pubmed: 32035028
Biochemistry. 2004 Apr 20;43(15):4568-74
pubmed: 15078103
Science. 2020 Jun 19;368(6497):1331-1335
pubmed: 32321856
Virus Res. 2016 Dec 2;226:117-127
pubmed: 27317167
FEBS J. 2014 Sep;281(18):4085-96
pubmed: 25039866
Biochemistry. 2010 May 25;49(20):4308-17
pubmed: 20420403
Biochem Pharmacol. 2020 Dec;182:114225
pubmed: 32956643
Antiviral Res. 2017 May;141:101-106
pubmed: 28216367
Biophys Chem. 2007 Dec;131(1-3):62-70
pubmed: 17904724
Biochem Biophys Res Commun. 2006 Jan 20;339(3):865-72
pubmed: 16329994
J Org Chem. 2010 Mar 19;75(6):1831-40
pubmed: 20039621
ACS Cent Sci. 2020 Mar 25;6(3):315-331
pubmed: 32226821
Bioorg Med Chem. 2006 Dec 15;14(24):8295-306
pubmed: 17046271
Acta Pharmacol Sin. 2020 Sep;41(9):1167-1177
pubmed: 32737471
J Biol Chem. 2010 Sep 3;285(36):28134-40
pubmed: 20489209
Acta Crystallogr D Biol Crystallogr. 2013 May;69(Pt 5):747-55
pubmed: 23633583
J Mol Biol. 2007 Feb 23;366(3):965-75
pubmed: 17189639
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Sci Rep. 2020 Dec 17;10(1):22200
pubmed: 33335206
J Biochem. 2008 Apr;143(4):525-36
pubmed: 18182387
Biochemistry. 2006 Dec 19;45(50):14908-16
pubmed: 17154528
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
EMBO J. 2002 Jul 1;21(13):3213-24
pubmed: 12093723
J Biol Chem. 2005 Jun 17;280(24):22741-8
pubmed: 15831489
J Clin Med. 2020 Apr 24;9(4):
pubmed: 32344679
Nat Commun. 2020 Nov 18;11(1):5877
pubmed: 33208735
PLoS One. 2010 Oct 06;5(10):e13197
pubmed: 20949131
FEBS Lett. 2004 Oct 22;576(3):325-30
pubmed: 15498556
Biosci Rep. 2018 Feb 21;38(1):
pubmed: 29298880
Viruses. 2021 Jan 24;13(2):
pubmed: 33498923
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481
Biochem Biophys Res Commun. 2004 Jun 11;318(4):862-7
pubmed: 15147951
Commun Biol. 2021 Jan 20;4(1):93
pubmed: 33473151
ACS Comb Sci. 2020 Jun 8;22(6):297-305
pubmed: 32402186
J Mol Biol. 1974 Jul 5;86(3):665-84
pubmed: 4368360
Virus Res. 2008 Apr;133(1):63-73
pubmed: 17397958
Sci Adv. 2020 Oct 16;6(42):
pubmed: 33067239
Sci Transl Med. 2020 Aug 19;12(557):
pubmed: 32747425

Auteurs

Juliana C Ferreira (JC)

Science Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.

Samar Fadl (S)

Science Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.

Adrian J Villanueva (AJ)

Science Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.

Wael M Rabeh (WM)

Science Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.

Classifications MeSH